Citations

Clear

634 citation(s) found for "Hall, A".

Abstract B028: Beyond the diagnosis: A town hall event to explore black men’s journey with prostate cancer and sexuality
Kaninjing, Ernie, Ghasemi, Parisa , Danker, Skyler, Morton, Daniel J. , Dwyer, Kathleen , Young, Mary Ellen , Odedina, Folakemi T., Siston, Amy, Cole, Perry , Beckford, Patrick , Reese, Donald , Montgomery, Everett , Odeleye, Roland , Ogunsanya, Motolani E. , Nyame, Yaw A. , Neil, Jordan M. , Alexander, Adam C. , Mitchell, Thomas J. , Kendzor, Darla E.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 21, 2024 | Volume: 33 | Issue: 9_Supplement | Pages: B028-B028

10.1158/1538-7755.disp24-b028 Get It

Abstract Introduction Prostate cancer (CaP) significantly impacts Black men, who face higher morbidity despite lower overall mortality. The disease and its treatments profoundly affect sexuality, relationships, and quality of life (QoL), necessitating robust support systems. Healthcare, spousal support, community involvement, and interactions with other survivors are crucial for enhancing survivors' self-esteem and daily functioning. Virtual town halls offer a platform to share trusted information and foster community support, overcoming geographic and structural barriers. This town hall event will explore Black CaP survivors' experiences, focusing on sexuality post-diagnosis and related medical and psychological needs. MethodsOn June 13, 2024, The University of Oklahoma and Stephenson Cancer Center will host the 5th town hall event (via Microsoft Teams) to address Black CaP survivors' sexual health concerns. Previous town halls averaged 70 attendees and covered various aspects of the CaP journey. This event will include storytelling and panel discussions, with presentations from two CaP survivors and their spouses on personal experiences and coping strategies. A urologic oncologist will discuss treatment advancements and early detection, while a clinical health psychologist will address psychological and emotional aspects of survivorship. Simultaneous watch parties will be held in Milledgeville, Georgia, and Dallas, Texas. Interactive Q&A sessions will allow participant engagement. Attendees will complete a post-event survey to assess the session's impact and collect clinical and sociodemographic data. Quantitative data will be analyzed using SPSS v28, and audio-recorded sessions will be transcribed and thematically analyzed using Nvivo. Results will be available by the end of June and presented at the conference. Expected Results Participants will gain a deeper understanding of the intersection between CaP and sexuality in Black men's health. Discussions will highlight the psychological impact of a cancer diagnosis, challenges in maintaining sexual health during and after treatment, and the role of mental health support. The town hall aims to emphasize the importance of a strong support system, providing valuable coping skills through shared experiences and expert insights. Topics will include the emotional and psychological impact of sexual health challenges, partner support, and the necessity of open communication with healthcare providers. The event seeks to improve CaP survivors' QoL by emphasizing continuous education and integrating sexual health into overall survivorship care. Conclusion This town hall event aims to bridge gaps in understanding and addressing Black CaP survivors' sexual health concerns. By fostering open dialogue and providing expert insights, we hope to improve these men's QoL and survivorship care, emphasizing mental health support, spousal support, and continuous education. Citation Format: Motolani Ogunsanya, Ernie Kaninjing, Parisa Ghasemi, Skyler Danker, Daniel Morton, Kathleen Dwyer, Mary Ellen Young, Folakemi T. Odedina, Yaw Nyame, Amy Siston, Jordan Neil, Adam C Alexander, Perry Cole, Patrick Beckford, Donald Reese, Thomas Mitchell, Everett Montgomery, Roland Odeleye, Darla E. Kendzor. Beyond the diagnosis: A town hall event to explore black men’s journey with prostate cancer and sexuality [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B028.
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024
Llor, Xavier , Abbass, Mohammad Ali , Chen, Christopher T. , Cooper, Gregory S. , Early, Dayna S., Friedman, Mark , Fudman, David , Giardiello, Francis M., Glaser, Kathryn , Gurudu, S, Hall, Michael J. , Issaka, Rachel B. , Kidambi, Trilokesh D. , Lazenby, Audrey J., Maratt, Jennifer K. , Markowitz, Arnold J. , Marsano, Joseph, Olortegui, Kinga Skowron , Peter, Shajan , Porter, Laura , Shafi, Mehnaz, Terdiman, Jonathan P., Vu, Peter , Wood, Elizabeth H., Cassara, Carly J., Gurudu, Surya, Ness, Reid M. , Bishu, Shrinivas , Huang, Lyen C. , Katona, Bryson W , May, Folasade P. , Mayer, Robert J. , Olortegui, Kinga S. , Patel, Swati , Stanich, Peter P. , Weiss, Jennifer M. , Wood, Elizabeth, Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 438-446

10.6004/jnccn.2024.0047 | PMID 39236750 Get It

The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC screening for patients without defined genetic syndromes. These NCCN Guidelines Insights focus on select recent updates to the NCCN Guidelines, including a section on primary and secondary CRC prevention, and provide context for the panel’s recommendations regarding the age at which to initiate screening in average-risk individuals and those with increased risk based on personal history of childhood, adolescent, and young adult cancer.
Proton Pencil Beam Scanning Facilitates the Safe Treatment of Extended Radiation Targets for Hodgkin Lymphoma: A Report from the Proton Collaborative Group Registry
Ebadi, Maryam , Pankuch, Mark , Boyer, Sean, Chang, J. , Stevens, Craig , Hall, Matthew D. , Bates, James E. , Flampouri, Stella , Kole, Adam J. , Mohindra, Pranshu , Rossi, Carl J., Sanghvi, Parag, McGee, L.A. , Rana, Zaker , Tseng, Yolanda D. , Kole, Adam J , Mohindra, Pranshu , McGee, Lisa, Tseng, Yolanda D , Hall, Matthew D , Hasan, Shaakir

Mayo Clinic

Cancers | August 1, 2024 | Volume: 16 | Issue: 15 | Pages: 2736

10.3390/cancers16152736 | PMID 39123464 Get It

Because proton beam therapy (PBT) can lower the dose of radiation to the heart, lungs, and breast, it is an established radiation modality for patients with Hodgkin lymphoma (HL). Pencil beam scanning (PBS) PBT facilitates the treatment of more extensive targets. This may be especially of value for lymphoma patients who require RT to both mediastinal and axillary targets, defined here as extended target RT (ETRT), given the target distribution and need to minimize the lung, heart, and breast dose. Using the Proton Collaborative Group registry, we identified patients with HL treated with PBT to both their mediastinum and axilla, for which DICOM-RT was available. All patients were treated with PBS. To evaluate the dosimetric impact of PBS, we compared delivered PBS plans with VMAT butterfly photon plans optimized to have the same target volume coverage, when feasible. Between 2016 and 2021, twelve patients (median 26 years) received PBS ETRT (median 30.6 Gy (RBE)). Despite the large superior/inferior (SI, median 22.2 cm) and left/right (LR, median 22.8 cm) extent of the ETRT targets, all patients were treated with one isocenter except for two patients (both with SI and LR > 30 cm). Most commonly, anterior beams, with or without posterior beams, were used. Compared to photons, PBS had greater target coverage, better conformity, and lower dose heterogeneity while achieving lower doses to the lungs and heart, but not to the breast. No acute grade 3+ toxicities were reported, including pneumonitis. Proton ETRT in this small cohort was safely delivered with PBS and was associated with an improved sparing of the heart and lungs compared to VMAT.
Tricuspid valve infective endocarditis in disseminated gonococcal infection (DGI)
Cummings, Shenae , Busby, Darin, Hall, Michael E. , Garrigos, Zerelda Esquer , Esquer Garrigos, Zerelda

Mayo Clinic

BMJ Case Reports | July 29, 2024 | Volume: 17 | Issue: 7 | Pages: e260638

10.1136/bcr-2024-260638 | PMID 39074945 Get It

Summary We describe a case of culture-negative infective endocarditis due to Neisseria gonorrhoeae, where the application of metagenomics shotgun sequencing in blood played a pivotal role in elucidating the underlying aetiology, guiding targeted therapy and ultimately resulting in the patient’s complete recovery. Beyond its immediate clinical impact, prompt treatment bears significant implications for public health. The utilisation of molecular testing emerges as a valuable strategy to enhance diagnostic accuracy, particularly in cases involving fastidious organisms that are infrequently associated with infective endocarditis.
BRCA1, BRCA2 , and Associated Cancer Risks and Management for Male Patients
Shevach, Jeffrey , Castro, Elena , Couch, Fergus J. , Domchek, Susan M., Eeles, Rosalind A. , Lin, Daniel W., Morgan, Todd M. , Offit, Kenneth, Schaeffer, Edward M. , Szymaniak, Brittany M. , Eeles, Rosalind A , Morgan, Todd M , Cheng, Heather H. , Couch, Fergus J. , Giri, Veda N. , Hall, Michael J. , King, Mary‐Claire , Lin, Daniel W., Loeb, Stacy , Offit, Kenneth, Pritchard, Colin C. , Vassy, Jason L. , Katona, Bryson W , Maxwell, Kara N.

Mayo Clinic

JAMA Oncology | July 25, 2024 | Volume: 10 | Issue: 9 | Pages: 1272

10.1001/jamaoncol.2024.2185 | PMID 39052257 Get It

Importance Half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in BRCA1 and BRCA2 (also known as pathogenic or likely pathogenic variants, referred to here as BRCA1/2 PVs) are well known to significantly increase the risk of breast and ovarian cancers in female carriers, and knowledge of BRCA1/2 PVs informs established cancer screening and options for risk reduction. While risks to male carriers of BRCA1/2 PVs are less characterized, there is convincing evidence of increased risk for prostate cancer, pancreatic cancer, and breast cancer in males. There has also been a rapid expansion of US Food and Drug Administration–approved targeted cancer therapies, including poly ADP ribose polymerase (PARP) inhibitors, for breast, pancreatic, and prostate cancers associated with BRCA1/2 PVs. Observations This narrative review summarized the data that inform cancer risks, targeted cancer therapy options, and guidelines for early cancer detection. It also highlighted areas of emerging research and clinical trial opportunities for male BRCA1/2 PV carriers. These developments, along with the continued relevance to family cancer risk and reproductive options, have informed changes to guideline recommendations for genetic testing and strengthened the case for increased genetic testing for males. Conclusions and Relevance Despite increasing clinical actionability for male carriers of BRCA1/2 PVs, far fewer males than female individuals undergo cancer genetic testing. Oncologists, internists, and primary care clinicians should be vigilant about offering appropriate genetic testing to males. Identifying more male carriers of BRCA1/2 PVs will maximize opportunities for cancer early detection, targeted risk management, and cancer treatment for males, along with facilitating opportunities for risk reduction and prevention in their family members, thereby decreasing the burden of hereditary cancer.
Validation of a Multimarker eGFR Equation in Preserved and Reduced eGFR Using the GENOA Cohort
Tio, Maria Clarissa , Zhu, Xiaoqian , Yen, Timothy E. , Hall, Michael E. , Rule, Andrew D. , Lirette, Seth T. , Obi, Yoshitsugu , Dossabhoy, Neville R. , Shafi, Tariq

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 34 | Issue: 11S | Pages: 665-666

10.1681/asn.20233411s1665c Get It

Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer
Lee, W. Robert , Dignam, James J., Amin, Mahul B. , Bruner, Deborah Watkins , Low, Daniel A. , Shah, Amit B. , D’Souza, David , Michalski, Jeff M. , Dayes, Ian S. , Seaward, Samantha A. , Hall, William A. , Nguyen, Paul L. , Pisansky, Thomas M. , Faria, Sergio , Chen, Yuhchyau , Rodgers, Joseph P., Bruner, Deborah , Swanson, Gregory P , Michalski, Jeff M , Dayes, Ian S , Seaward, Samantha A , Hall, William A , Sandler, Howard M , Swanson, Gregory P. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | May 17, 2024 | Volume: 42 | Issue: 20 | Pages: 2377-2381

10.1200/jco.23.02445 | PMID 38759121 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. NRG Oncology RTOG 0415 is a randomized phase III noninferiority (NI) clinical trial comparing conventional fractionation (73.8 Gy in 41 fractions) radiotherapy (C-RT) with hypofractionation (H-RT; 70 Gy in 28) in patients with low-risk prostate cancer. The study included 1,092 protocol-eligible patients initially reported in 2016 with a median follow-up of 5.8 years. Updated results with median follow-up of 12.8 years are now presented. The estimated 12-year disease-free survival (DFS) is 56.1% (95% CI, 51.5 to 60.5) for C-RT and 61.8% (95% CI, 57.2 to 66.0) for H-RT. The DFS hazard ratio (H-RT/C-RT) is 0.85 (95% CI, 0.71 to 1.03), confirming NI ( P < .001). Twelve-year cumulative incidence of biochemical failure (BF) was 17.0% (95% CI, 13.8 to 20.5) for C-RT and 9.9% (95% CI, 7.5 to 12.6) for H-RT. The HR (H-RT/C-RT) comparing biochemical recurrence between the two arms was 0.55 (95% CI, 0.39 to 0.78). Late grade ≥3 GI adverse event (AE) incidence is 3.2% (C-RT) versus 4.4% (H-RT), with relative risk (RR) for H-RT versus C-RT 1.39 (95% CI, 0.75 to 2.55). Late grade ≥3 genitourinary (GU) AE incidence is 3.4% (C-RT) versus 4.2% (H-RT), RR 1.26 (95% CI, 0.69 to 2.30). Long-term DFS is noninferior with H-RT compared with C-RT. BF is less with H-RT. No significant differences in late grade ≥3 GI/GU AEs were observed between assignments (ClinicalTrials.gov identifier: NCT00331773 ).
Quantifying Individual-Level Uncertainty in GFR Estimation
Zhu, Xiaoqian , Mosley, Tom, Butler, Javed , Hall, Michael E. , Vaitla, Pradeep , Lirette, Seth T. , Rule, Andrew D. , Butler, Kenneth R. , Wynn, James J., Dossabhoy, Neville R. , Güallar, Eliseo , Shafi, Tariq

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 19-19

10.1681/asn.20213210s119a Get It

Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC–Alarmin Axis
Vincelette, Nicole D. , Yu, Xiaoqing , Moon, Jungwon , Su, Siyuan , Cheng, Chia‐Ho, Sammut, Rinzine , Razabdouski, Tiffany N. , Nguyen, Hai V. , Eksioglu, Erika A. , Ali, Najla Al , Patel, Parth , Lee, Dae Hyun , Nakanishi, Shima , Hyjek, Elizabeth , Murphy, Daniel J. , Lee, Daesung , Kuykendall, Andrew , Moon, Jungwon , Su, Siyuan , Cheng, Chia-Ho , Sammut, Rinzine , Razabdouski, Tiffany N , Nguyen, Hai V , Eksioglu, Erika A , Chan, Onyee , Al Ali, Najla , Patel, Parth C , Lee, Dae H , Nakanishi, Shima , Ferreira, Renan B , Hyjek, Elizabeth , Mo, Qianxing , Cory, Suzanne , Lawrence, Harshani R , Zhang, Ling , Murphy, Daniel J , Komrokji, Rami S , Lee, Daesung , Kaufmann, Scott H , Cleveland, John L , Yun, Seongseok , Chan, Onyee , Zhang, Ling , Komrokji, Rami S. , Kaufmann, Scott H. , Cleveland, John L. , Yun, Seongseok

Mayo Clinic

Blood Cancer Discovery | May 7, 2024 | Volume: 5 | Issue: 4 | Pages: 276-297

10.1158/2643-3230.bcd-23-0210 | PMID 38713018 Get It

Abstract Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPN) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies, particularly for patients with triple-negative (TN) myelofibrosis (MF) who lack mutations in the JAK2 kinase pathway and have very poor clinical outcomes. Here we report that MYC copy number gain and increased MYC expression frequently occur in TN-MF and that MYC-directed activation of S100A9, an alarmin protein that plays pivotal roles in inflammation and innate immunity, is necessary and sufficient to drive development and progression of MF. Notably, the MYC-S100A9 circuit provokes a complex network of inflammatory signaling that involves numerous hematopoietic cell types in the bone marrow microenvironment. Accordingly, genetic ablation of S100A9 or treatment with small molecules targeting the MYC-S100A9 pathway effectively ameliorates MF phenotypes, highlighting the MYC–alarmin axis as a novel therapeutic vulnerability for this subgroup of MPNs. Significance: This study establishes that MYC expression is increased in TN-MPNs via trisomy 8, that a MYC-S100A9 circuit manifest in these cases is sufficient to provoke myelofibrosis and inflammation in diverse hematopoietic cell types in the BM niche, and that the MYC-S100A9 circuit is targetable in TN-MPNs.
Ciliopathy patient variants reveal organelle-specific functions for TUBB4B in axonemal microtubules
Dodd, Daniel O , Mechaussier, Sabrina , Yeyati, Patricia L. , McPhie, Fraser , Anderson, Jacob R. , Khoo, Chen Jing , Shoemark, Amelia , Gupta, Deepesh Kumar , Attard, Thomas, Zariwala, Maimoona A. , Legendre, Marie , Bracht, Diana , Gui, Miao , Parry, David , Black, Holly A. , Mitri-Frangieh, Rana, Faucon, Catherine, Kaplan, Josseline, Megaw, Roly , Mohamed, Mai A., Aitken, Stuart , Gautier, Philippe , Reinholt, Finn R., Hirst, Robert A. , O’Callaghan, Chris, Bottier, Mathieu , Escudier, Estelle , Crowley, Suzanne , Descartes, Maria , Kenia, Priti , Amiel, Jeanne , Bacci, Giacomo Maria , Calogero, Claudia , Palazzo, Viviana , Tiberi, Lucia , Blümlein, Ulrike, Rogers, Andrew, Wenger, David A. , Fulton, Anne B. , Rosenfeld, Margaret , Holm, Ingrid A., Quigley, Alan J. , Murphy, Laura C. , Cassidy, Diane M. , Kriegsheim, Alex von , Partnership, Scottish Genomes, Network, Undiagnosed Diseases, Murris, Marlène , Hogg, Claire , Macleod, Kenneth , Urquhart, Don S. , Unger, Stefan , Amselem, Serge , Leigh, Margaret W. , Knowles, Michael R. , Mitchison, Hannah M. , Rozet, Jean‐Michel , Mill, Pleasantine , Gupta, Deepesh K , Wallmeier, Julia , Fassad, Mahmoud R , Tennant, Peter A , Meynert, Alison , Wheway, Gabrielle , Fares-Taie, Lucas , Black, Holly A , Patel, Mitali , McKie, Lisa , Megaw, Roly , Aitken, Stuart , Gautier, Philippe , Heimdal, Ketil , Bottier, Mathieu , Escudier, Estelle , Crowley, Suzanne , Descartes, Maria , Jabs, Ethylin W , Bacci, Giacomo Maria , Calogero, Claudia , Tiberi, Lucia , Wambach, Jennifer A , Wegner, Daniel J , Fulton, Anne B , Kenna, Margaret , Quigley, Alan , Hall, Emma A , Murphy, Laura C , Cassidy, Diane M , von Kriegsheim, Alex , Pasquier, Laurent , Murris, Marlène S , Chalmers, James D , Hogg, Claire , Macleod, Kenneth A , Urquhart, Don S , Unger, Stefan , Aitman, Timothy J , Leigh, Margaret W , Omran, Heymut , Mitchison, Hannah M , Brown, Alan , Marsh, Joseph A , Ti, Shih-Chieh , Horani, Amjad , Rozet, Jean-Michel , Perrault, Isabelle , Mill, Pleasantine , Dodd, Daniel O. , Mechaussier, Sabrina , Gatsogiannis, Christos , Holm, Ingrid A., Partnership, Scottish Genomes, Network, Undiagnosed Diseases, Papon, Jean‐François , Pasquier, Laurent , Chalmers, James D. , Omran, Heymut , Welburn, Julie P. I.

Mayo Clinic

Science | April 25, 2024 | Volume: 384 | Issue: 6694 | Pages: No page available

10.1126/science.adf5489 | PMID 38662826 Get It

Tubulin, one of the most abundant cytoskeletal building blocks, has numerous isotypes in metazoans encoded by different conserved genes. Whether these distinct isotypes form cell type– and context-specific microtubule structures is poorly understood. Based on a cohort of 12 patients with primary ciliary dyskinesia as well as mouse mutants, we identified and characterized variants in the TUBB4B isotype that specifically perturbed centriole and cilium biogenesis. Distinct TUBB4B variants differentially affected microtubule dynamics and cilia formation in a dominant-negative manner. Structure-function studies revealed that different TUBB4B variants disrupted distinct tubulin interfaces, thereby enabling stratification of patients into three classes of ciliopathic diseases. These findings show that specific tubulin isotypes have distinct and nonredundant subcellular functions and establish a link between tubulinopathies and ciliopathies.